Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Jul 23:13:1297-1302.
doi: 10.2147/OPTH.S187364. eCollection 2019.

Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights

Joel M Mor  1 , Alexander C Rokohl  1 , Konrad R Koch  1 , Ludwig M Heindl  1   2
Affiliations
Review

Sentinel lymph node biopsy in the management of conjunctival melanoma: current insights

Joel M Mor et al. Clin Ophthalmol. .

Abstract

Purpose: To evaluate the role of sentinel lymph node biopsy (SLNB) in conjunctival melanoma (CM). Methods: This article provides a review of the literature from PUBMED. Results: Data on SLNB in the management of CM are scarce and only two relatively large cohorts have been reported. Although indication criteria for SLNB vary slightly, positive findings can be expected in 11%-13% of CM cases, including small tumors. False negative SLNB findings are rare (<10%). Failure to identify SLNB has been attributed to the surgical learning curve and recurrent tumors with scar tissue impeding spread of the tracer material. Reported 5-year survival rate following CM management including SLNB, is up to 79%, but there are no comparative cohort studies proving the assumed benefit. Adverse events reported were non-severe and transient. Conclusion: Patients can potentially benefit from SLNB and the procedure can be offered to eligible patients. However, there is not enough evidence to support SLNB as a mandatory part of CM management.

Keywords: biopsy; conjunctival melanoma; lymph node; lymphatic spread; sentinel.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Melanoma of the temporal bulbar conjunctiva with a prominent feeder vessel in the left eye of a patient.
See this image and copyright information in PMC

References

    1. Mor JM, Heindl LM. Systemic BRAF/MEK inhibitors as a potential treatment option in metastatic conjunctival melanoma. Ocul Oncol Pathol. 2017;3:133–141. doi:10.1159/000452473 - DOI - PMC - PubMed
    1. Triay E, Bergman L, Nilsson B, All-Ericsson C, Seregard S. Time trends in the incidence of conjunctival melanoma in Sweden. Br J Ophthalmol. 2009;93:1524–1528. doi:10.1136/bjo.2009.157933 - DOI - PubMed
    1. Norregaard JC, Gerner N, Jensen OA, Prause JU. Malignant melanoma of the conjunctiva: occurrence and survival following surgery and radiotherapy in a Danish population. Graefes Arch Clin Exp Ophthalmol. 1996;234:569–572. - PubMed
    1. Shields JA, Shields CL, De Potter P. Surgical management of conjunctival tumors. The 1994 Lynn B McMahan lecture. Arch Ophthalmol. 1997;115:808–815. doi:10.1001/archopht.1997.01100150810025 - DOI - PubMed
    1. Heindl LM, Koch KR, Schlaak M, Mauch C, Cursiefen C. [Adjuvant therapy and interdisciplinary follow-up care of conjunctival melanoma]. Ophthalmologe. 2015;112:907–911. - PubMed

LinkOut - more resources